Detalles de la búsqueda
1.
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018.
Ann Hepatol;
29(1): 101154, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37742743
2.
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
J Hepatol;
79(4): 888-897, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37355043
3.
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
Pediatr Diabetes;
23(2): 173-182, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779087
4.
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Pediatr Diabetes;
23(2): 183-193, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779103
5.
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Diabetes Obes Metab;
23(9): 2099-2108, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34033212
6.
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Diabetes Obes Metab;
23(6): 1342-1350, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33565686
7.
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.
Diabetes Obes Metab;
23(6): 1242-1251, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512755
8.
Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin.
Diabetes Obes Metab;
21(2): 408-411, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30178570
9.
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Diabetes Obes Metab;
21(5): 1128-1135, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30609212
10.
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Diabetes Obes Metab;
21(4): 781-790, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30393950
11.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med;
373(3): 232-42, 2015 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26052984
12.
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Diabetes Obes Metab;
20(5): 1111-1120, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29266675
13.
Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival.
Diabetes Obes Metab;
20(4): 821-830, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29119713
14.
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Diabetes Obes Metab;
20(12): 2876-2884, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019498
15.
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Diabetes Obes Metab;
20(3): 530-540, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28921862
16.
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
Diabetes Obes Metab;
20(10): 2379-2388, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29923323
17.
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Cardiovasc Diabetol;
16(1): 112, 2017 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28893244
18.
Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.
Diabetes Obes Metab;
19(10): 1425-1435, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28497592
19.
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Diabetes Obes Metab;
19(3): 394-400, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28093853
20.
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Diabetes Obes Metab;
19(11): 1587-1593, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28432745